Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Issued Date
2022-10-15
Resource Type
ISSN
00221899
eISSN
15376613
Scopus ID
2-s2.0-85139343905
Pubmed ID
35267040
Journal Title
Journal of Infectious Diseases
Volume
226
Issue
8
Start Page
1372
End Page
1381
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infectious Diseases Vol.226 No.8 (2022) , 1372-1381
Suggested Citation
Assawakosri S., Kanokudom S., Suntronwong N., Auphimai C., Nilyanimit P., Vichaiwattana P., Thongmee T., Duangchinda T., Chantima W., Pakchotanon P., Srimuan D., Thatsanatorn T., Klinfueng S., Yorsaeng R., Sudhinaraset N., Wanlapakorn N., Mongkolsapaya J., Honsawek S., Poovorawan Y. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. Journal of Infectious Diseases Vol.226 No.8 (2022) , 1372-1381. 1381. doi:10.1093/infdis/jiac092 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85451
Title
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Other Contributor(s)
Abstract
Background: The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants. Methods: A total of 224 individuals who completed the 2-dose CoronaVac for 6 months were included. We studied reactogenicity and immunogenicity after a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (AZD1222), and the messenger ribonucleic acid (mRNA) vaccine (both BNT162B2 and mRNA-1273). We also determined immunogenicity at 3- and 6-month boosting intervals. Results: The solicited adverse events were mild to moderate and well tolerated. Total receptor binding domain (RBD) immunoglobulin (Ig), anti-RBD IgG, focus reduction neutralization test (FRNT50) against delta and omicron variants, and T-cell response were highest in the mRNA-1273 group followed by the BNT162b2, AZD1222, and BBIBP groups, respectively. We also witnessed a higher total Ig anti-RBD in the long-interval than in the short-interval group. Conclusions: All 4 booster vaccines significantly increased binding and neutralizing antibodies in individuals immunized with 2 doses of CoronaVac. The present evidence may benefit vaccine strategies to thwart variants of concern, including the omicron variant.